Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
kH9CuPLjW0MudvaY
Listen
